Real world data show that immunotherapy leads to better overall survival outcomes than chemotherapy in patients with ...

This is part of a multibillion-rand plan to fill connectivity gaps in the country and increase internet access.

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

We recently published a list of the 10 Worst Performing Defense Stocks So Far in 2025. In this article, we will take a look ...

Early clinical results suggest the firm's antibodies targeting the Vβ T-cell receptor could induce strong and durable responses in cancer patients.

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial data from its Phase 1/2 study.

Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor ...

The world’s longest quantum communications link has been set up between China and South Africa, spanning a record-breaking 12,900 km (8,015 miles). The connection takes advantage of quantum physics ...

Biliary Tract Cancer (BTC): KEYTRUDA may be combined with chemotherapy medicines to treat BTC, a cancer that affects the bile ducts or gallbladder. This treatment is for adults when the cancer has ...

Durable complete response (CR) in a MCC patient treated with 15 mg/kg solnerstotug + cemiplimab. Patient continues on ...

A phase 2 trial will evaluate leronlimab’s safety and efficacy for the treatment of patients with microsatellite stable ...